Morishima Naoki, Kamada Yoshihiro, Ota Hiyori, Iwagami Yoshifumi, Takahashi Hidenori, Shimosaka Munefumi, Sakon Daisuke, Kondo Jumpei, Yamada Makoto, Kumada Takashi, Eguchi Hidetoshi, Miyoshi Eiji
Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Pract Lab Med. 2024 May 18;40:e00402. doi: 10.1016/j.plabm.2024.e00402. eCollection 2024 May.
Chronic inflammation of the pancreas is considered to be one of the causes of pancreatic cancer. However, the diagnosis of chronic pancreatitis (CP) is very difficult in the pancreas, where biopsies are difficult to perform. The prevalence of CP is estimated to be many times more common than in patients with actual symptomatic CP. In recent years, abnormal cleavage of certain proteins has attracted attention as a biomarker for CP other than pancreatic enzymes. Connective tissue growth factor (CTGF) is one of the growth factors involved in tissue repair and other processes and is increased by stimulation of transforming growth factor-β, suggesting a relationship of CTGF with fibrosis. In this study, we measured the total length of CTGF in blood and -terminal fragment CTGF in 48 cases of chronic pancreatitis, 64 cases of pancreatic cancer and 45 healthy volunteers (HV). Interestingly, we found that blood -terminal fragment CTGF level was significantly increased in CP and pancreatic cancer patients. Multiple logistic regression analysis showed serum levels of -terminal fragment CTGF, CRP and amylase were significant and independent variables for the differential diagnosis of CP from HV. Receiver operating characteristic analysis showed that area under the curve (AUC) value of serum -terminal fragment CTGF level was 0.933, which can differentiate between CP and HV. Several factors would be involved in the increase in serum -terminal fragment CTGF level. In conclusion, serum -terminal fragment CTGF level is a promising new biomarker for CP.
胰腺的慢性炎症被认为是胰腺癌的病因之一。然而，在胰腺中慢性胰腺炎（CP）的诊断非常困难，因为很难进行活检。据估计，CP的患病率比有实际症状的CP患者高出许多倍。近年来，某些蛋白质的异常裂解作为CP的生物标志物受到关注，它不同于胰腺酶。结缔组织生长因子（CTGF）是参与组织修复和其他过程的生长因子之一，并且通过转化生长因子-β的刺激而增加，这表明CTGF与纤维化有关。在本研究中，我们测量了48例慢性胰腺炎患者、64例胰腺癌患者和45名健康志愿者（HV）血液中CTGF的全长和CTGF的N末端片段。有趣的是，我们发现CP患者和胰腺癌患者血液中的N末端片段CTGF水平显著升高。多因素logistic回归分析显示，血清N末端片段CTGF、CRP和淀粉酶水平是CP与HV鉴别诊断的显著且独立的变量。受试者工作特征分析显示，血清N末端片段CTGF水平的曲线下面积（AUC）值为0.933，可区分CP和HV。血清N末端片段CTGF水平升高可能涉及多种因素。总之，血清N末端片段CTGF水平是一种很有前景的CP新生物标志物。
